NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M

NeuroPace Inc

2022-Q3 EPS reported -$1.47 revenue$32,731,000

Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.
Net loss $11.8M vs $8.1M prior year; operating expenses $18.2M vs $13.8M.
Cash and equivalents $85.4M, down from $92.4M at June 30; long-term debt $52.0M.
Gross margin 71% vs 73% due to short-term supply chain disruption, now resolved.
Initiated distribution of DIXI Medical stereo EEG electrodes on Oct 1, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NeuroPace Inc reported the quarter ending September 30, 2022 results: revenue $11.2 million, net income $11.8 million. Guidance raised.

Period: the quarter ending September 30, 2022
Revenue: $11.2 million
Net income: $11.8 million
Guidance: raised
Result: reported results

Exact text from the filing

the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Recent Highlights • Achieved total revenue of $11.2 million for the third quarter of 2022, representing growth of 8% compared to the third quarter of 2021 and 9% compared to the second quarter of 2022 • Achieved initial implant revenue of

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-22-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.